Remote Assessment of Cognitive Function Feasible With Hematologic Malignancies
Researchers demonstrated the feasibility of remote cognitive assessments in patients with hematologic malignancies.
Multiple Myeloma
Significant Treatment Attrition Seen in Multiple Myeloma
Among patients who did not undergo autologous stem cell transplant, 52.7% advanced to second-line treatment.
Lenalidomide Associated With Second Primary Malignancies in MM, Not Other Cancers
Lenalidomide increases the risk of developing a second primary malignancy in patients with multiple myeloma, a meta-analysis suggests.
Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma
Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
T-Cell Engaging Therapies Show Promise as Salvage After CAR-T Therapy in MM
Patients with multiple myeloma that relapses after BCMA-directed CAR T-cell therapy may benefit from salvage treatment with additional T cell-engaging therapies.
Older MM Patients Have More Advanced Disease, Worse Outcomes in Real World vs RCTs
Multiple myeloma patients age 75 and older present with more advanced disease and have worse outcomes in the real world than in clinical trials, a study suggests.
Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Proton FLASH Radiotherapy Deemed Feasible, Comparable to Conventional Dose Rate Radiotherapy
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
Tecvayli Approved for Relapsed or Refractory Multiple Myeloma
The approval was based on data from the MajesTEC-1 study, which included 110 adults with relapsed or refractory multiple myeloma who had previously received at least 3 prior therapies.
Oncology Care Model Failed to Account for Patient and Disease Complexity, Researchers Say
Critical variables for 3 of the highest-volume cancers were not measured under the Oncology Care Model, according to researchers.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...